Pain relief in oral mucositis
OncoZenge develops better products for cancer supportive care. Preparations for Phase 3 is ongoing for our lead asset BupiZenge® following superior Phase 2 data vs Standard of care in patients with oral mucositis.
5 million people worldwide suffer from oral mucositis after cancer therapy. Oral mucositis is the most debilitating side effect of radiation therapy and chemotherapy. After radiotherapy in the head and neck region, 90% of patients develop OM and of the patients treated with chemotherapy, about 30% are affected. OM causes severe pain, interruption of cancer treatments and increased healthcare costs.
Calendar/Presentations
Next Caledar Event: 2022-08-16
Interim report for January – June 2022
OM causes severe pain
Oral mucositis has a significant impact on the quality of life of cancer patients. It may cause severe pain, difficulties in eating and drinking as well as in swallowing and communicating. OM leads to:
- 62% of patients need to be hospitalized*
- 70% of patients need tube feeding*
- 35% of patients must reduce the dose or discontinue their cancer treatment*
In clinical studies, BupiZenge® has been shown to significantly reduce pain in the mouth and throat.
*Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M. Perspectives on cancer therapy-induced mucosal injury. Cancer. 2004;100(9 Suppl):1995-2025
PRESS RELEASES
2022-04-22
ONCOZENGE AB INTERIM REPORT JANUARY-MARCH 2022
2022-04-22
ONCOZENGE BEGINS REFORMULATION OF BUPIZENGE®, INITIATES PROCESS TO BROADEN THE COMPANY’S OPERATIONS AND POSTPONES THE ANNUAL GENERAL MEETING
2022-04-12
ONCOZENGE DISCONTINUE THE PLANNED PATIENT STUDY WITH BUPIZENGE®
2022-02-15
ONCOZENGE YEAR-END REPORT FOR THE FINANCIAL YEAR 2021
2022-02-15
ONCOZENGE INITIATES TOXICITY STUDY AND ANNOUNCES MODIFICATION TO THE CLINICAL PLAN
2021-12-07
BULLETIN FROM ONCOZENGE´S EXTRAORDINARY GENERAL MEETING ON DECEMBER 7, 2021
2021-11-22
PAUL DE POTOCKI NEW CEO FOR ONCOZENGE AB
2021-11-22
NOTICE OF EXTRAORDINARY GENERAL MEETING IN ONCOZENGE AB
History
OncoZenge is a Swedish pharmaceutical company founded in 2020 as a spin-out from Moberg Pharma in collaboration with leading clinicians from Hvidovre Hospital in Denmark.
The original invention was made in 2011 by Professor Ove Andersen and his team who developed a novel concept to provide better pain relief for patients with OM. Since then clinical studies in Phase 1 and Phase 2 have demonstrated the efficacy and safety of BupiZenge®.
Subscribe to press releases & financial reports
Add your e-mail adress to get the latest news and reports
OncoZenge´s vision
BupiZenge® can radically improve quality of life for patients with severe oral pain, originating for example from radiation therapy or chemotherapy of cancer.
More about our main project BupiZenge® here